Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs

Digestive Diseases and Sciences

Volumn 43, Issue 8, 1998, Pages 1806-1813

  Larsen, Kenneth R ^a   Dajani, Esam Z ^b   Dajani, Nora E ^b   Dayton, Merril T ^b   Moore, John G ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Carbidopa; Catechol O methyltransferase; Electrolyte transport; Fluid transport; Intestine; L dopa; Parkinson's disease; Sinemet; Thiry Vella; Tolcapone

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; TOLCAPONE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; ELECTROLYTE TRANSPORT; FLUID TRANSPORT; INTESTINE ABSORPTION; INTESTINE SECRETION; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0031852535     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018852223902     Document Type: Article

References (17)

1. Borgulya J, Da Prada M, Dingemanse J, Scherschlicht R, Schlappi B, Zurcher G: Ro40-7592: Catecholamine-O-methyltransferase (COMT) inhibitor. Drugs Future 16:719-721, 1991
2. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S: Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A multicenter double-blind, placebo-controlled, multicenter trial. Neurology 49:1066-1071, 1997
3. Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G: COMT inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 63:421-428, 1997
4. Gullikson G, Dajani EZ, Bianchi RG: Inhibition of intestinal secretion in the dog: A new approach for the management of diarrhea! states. J Pharmacol Exp Ther 219:591-597, 1981
5. Bright-Asare P, Binder HJ: Stimulation of colonie secretion of water and electrolytes by hydroxy fatty acids. Gastroenterology 64:81-88, 1973
6. Thomas MV: Arsenazo III forms 2:1 complexes with calcium and 1:1 complexes with magnesium under physiological conditions. Biophys J 25:541-548, 1979
7. Zilversmit DB, Davis AK: Micro-determination of plasma phospholipid by trichloroacetic acid precipitation. J Lab Chem Med 35:155-160, 1950
8. Taylor JA, Mir GN: Alpha adrenergic receptors and gastric function. Drug Dev Res 2:105-122, 1982
9. Schultz E: Catechol-O-methyl transferase and aromatic-L-amino acid decarboxylase activities in human GI tissue. Life Sci 49(10):721-725, 1991
10. Flemstrom G, Safsten B: Role of dopamine and other stimuli of mucosal bicarbonate secretion in duodenal protection. Dig Dis Sci 39:1839-1842, 1994
11. Flemstrom G, Safsten B, Jedstedt G: Stimulation of mucosal alkaline secretion in rat duodenum by dopamine and dopaminergic compounds. Gastroenterology 104:825-833, 1993
12. Gorelick FS, Jamieson JD: Structure-function relationships of the pancreas. In Physiology of the Gastrointestinal Tract. LR Johnson (ed), New York, Raven Press, 1981, pp 773-794
13. Aho PA, Linden IB: Role of gastric mucosal eicosanoid production in the cytoprotection induced by nitecapone. Scand J Gastroenterol 27(2):134-138, 1992
14. Dajani EZ: Misoprostol: Pharmacology, pharmacokinetics and mechanisms of action. Exp Clin Gastroenterol 1:97-106, 1991
15. Dajani EZ, Wilson DM, Agrawal NM: Prostaglandins: An overview of the worldwide clinical experience. J Assoc Acad Minor Physicians 2:23-25, 1991
16. Dajani EZ, Roge EAW, Bertermann RL: Effects of E-prostaglandins, diphenoxylate and morphine on intestinal motility in vivo. Eur J Pharmacol 34:105-113, 1975
17. Slomiany BL, Liau YH, Lopez RA, Slomiany A: Nitecapone effect on the synthesis and secretion of gastric sulfomucin. Gen Pharmacol 14:69-73, 1993